These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24639563)

  • 1. More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer.
    Shen CT; Qiu ZL; Luo QY
    Endocr Relat Cancer; 2014 Apr; 21(2):L3-4. PubMed ID: 24639563
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    Shen CT; Qiu ZL; Luo QY
    Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
    de la Fouchardière C
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S34-9. PubMed ID: 26826481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New era for treatment in differentiated thyroid cancer.
    Haraldsdottir S; Shah MH
    Lancet; 2014 Jul; 384(9940):286-8. PubMed ID: 24768111
    [No Abstract]   [Full Text] [Related]  

  • 7. [Lenvatinib in radioiodine refractory thyroid carcinomas].
    de la Fouchardiere C
    Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib: 10 years after the first pivotal trial.
    Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
    Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label use of Sorafenib in patients with advanced thyroid carcinoma: Retrospective analysis of five cases.
    Bugalho MJ
    J Cancer Res Ther; 2016; 12(2):1084-7. PubMed ID: 27461704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge.
    Marotta V; Colao A; Faggiano A
    Endocrine; 2015 Dec; 50(3):824-5. PubMed ID: 25754914
    [No Abstract]   [Full Text] [Related]  

  • 11. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
    Hewett Y; Ghimire S; Farooqi B; Shah BK
    J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib for the treatment of thyroid cancer: an updated review.
    Krajewska J; Handkiewicz-Junak D; Jarzab B
    Expert Opin Pharmacother; 2015 Mar; 16(4):573-83. PubMed ID: 25605317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
    García-Martín A; López-Ibarra Lozano PJ; Triviño-Ibáñez EM; Escobar-Jiménez F
    Endocrinol Nutr; 2013 Mar; 60(3):152-3. PubMed ID: 22565118
    [No Abstract]   [Full Text] [Related]  

  • 14. Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.
    Matrone A; Valerio L; Pieruzzi L; Giani C; Cappagli V; Lorusso L; Agate L; Puleo L; Viola D; Bottici V; Del Re M; Molinaro E; Danesi R; Elisei R
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):319-334. PubMed ID: 28911728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
    Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib (Nexavar) for thyroid cancer.
    Med Lett Drugs Ther; 2014 May; 56(1443):43-4. PubMed ID: 24869715
    [No Abstract]   [Full Text] [Related]  

  • 17. Sorafenib for patients with differentiated thyroid cancer.
    Lee HJ; Ryu H; Choi YS; Song IC; Yun HJ; Jo DY; Kim S
    Lancet; 2015 Jan; 385(9964):228. PubMed ID: 25706707
    [No Abstract]   [Full Text] [Related]  

  • 18. Sorafenib for patients with differentiated thyroid cancer.
    Boudou-Rouquette P; Thomas-Schoemann A; Bellesoeur A; Goldwasser F
    Lancet; 2015 Jan; 385(9964):227-8. PubMed ID: 25706704
    [No Abstract]   [Full Text] [Related]  

  • 19. Sorafenib for patients with differentiated thyroid cancer.
    Huillard O; Blanchet B; Durand JP; Goldwasser F
    Lancet; 2015 Jan; 385(9964):227. PubMed ID: 25706705
    [No Abstract]   [Full Text] [Related]  

  • 20. Sorafenib in the treatment of thyroid cancer.
    Ferrari SM; Politti U; Spisni R; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Expert Rev Anticancer Ther; 2015; 15(8):863-74. PubMed ID: 26152651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.